Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease.

BACKGROUND The JELIS trial examined the preventive effects of eicosapentaenoic acid (EPA) on coronary artery disease (CAD) in hypercholesterolemia. Previous investigators have reported that patients with peripheral artery disease (PAD) have a poor prognosis due to the potential risk for CAD. We conducted a subanalysis to examine whether the incidence of CAD was high in patients with PAD and whether EPA prevented the occurrence of CAD. METHODS AND RESULTS Of 18,645 the Japan EPA lipid intervention study (JELIS) patients, 223 had PAD (control group; complicated (n=77), newly diagnosed (n=29), EPA group; complicated (n=96), newly diagnosed (n=21)). We analyzed the incidence of major coronary events (MCE) in the 2 groups. Cox proportional hazard ratio adjusted for baseline risk factor levels was used to test differences between the 2 groups. The incidence of MCE in the control group was significantly higher in patients complicated with PAD and in those newly diagnosed with PAD than in patients without PAD (complicated: hazard ratio 1.97, P=0.039; newly diagnosed: hazard ratio 2.88, P=0.030). As for patients with PAD, the EPA group had a significantly lower MCE hazard ratio than the control group (hazard ratio 0.44, 95% confidence interval 0.19-0.97, P=0.041). CONCLUSIONS Subanalysis of the JELIS trial demonstrated that in patients with PAD the incidence of CAD was higher than in controls, and that EPA markedly reduced the occurrence of CAD in those patients.

[1]  Y. Matsuzawa,et al.  Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). , 2008, Atherosclerosis.

[2]  Y. Matsuzawa,et al.  Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia. , 1992, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[3]  J. Bisbe,et al.  Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: findings from the FRENA registry , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[4]  H. Origasa,et al.  Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). , 2003, American heart journal.

[5]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[6]  S. Kusachi,et al.  Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[7]  W. Kannel,et al.  The Demographics of Claudication and the Aging of the American Population , 1996, Vascular medicine.

[8]  R. Kawamori,et al.  Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. , 2007, Atherosclerosis.

[9]  L. Norgren,et al.  Inter-society consensus for the management of peripheral arterial disease. , 2007, International angiology : a journal of the International Union of Angiology.

[10]  T. Yano,et al.  Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells, smooth muscle cells and fibrous components in rabbits caused by all-cis-5, 8, 11, 14, 17-icosapentaenoic acid. , 2002, Journal of atherosclerosis and thrombosis.

[11]  H. Nihei,et al.  Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[12]  A. J. Hulbert,et al.  Dietary fats and membrane function: implications for metabolism and disease , 2005, Biological reviews of the Cambridge Philosophical Society.

[13]  S. Takagi,et al.  Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. , 2004, Atherosclerosis.

[14]  S. Joshi‐Barve,et al.  Eicosapentaenoic Acid Prevents LPS-Induced TNF-α Expression by Preventing NF-κB Activation , 2004, Journal of the American College of Nutrition.

[15]  T. Terano,et al.  Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. , 1986, Progress in lipid research.

[16]  J. Ferrendelli,et al.  Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[17]  W. Seeger,et al.  Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. , 1996, Biochemical pharmacology.

[18]  Y. Matsuzawa,et al.  Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[19]  Adel A. Ahmed,et al.  Prevalence of Metabolic Syndrome in Patients With Clinically Advanced Peripheral Vascular Disease , 2008, Angiology.

[20]  John V. White,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[21]  D. Eguchi,et al.  Perioperative use of eicosapentaenoic acid and patency of infrainguinal vein bypass: A retrospective chart review. , 2007, Current therapeutic research, clinical and experimental.

[22]  Kortaro Tanaka,et al.  Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients: Subanalysis of the JELIS Trial , 2008, Stroke.

[23]  Deepak L. Bhatt,et al.  Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[24]  P. Calder,et al.  Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial , 2003, The Lancet.

[25]  T. Hamazaki,et al.  Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. , 1983, Atherosclerosis.

[26]  T. Kohro,et al.  Eicosapentaenoic acid (EPA) in reducing secondary cardiovascular events in hypercholesterolemic Japanese patients. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[27]  R. Langer,et al.  Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease , 1992 .